GSK tests new vaccine combo to fight chronic hepatitis b

NCT ID NCT03866187

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested a new combination of therapeutic vaccines in adults with chronic Hepatitis B who were already taking antiviral pills. The main goals were to check the safety of the vaccines and see if they could help the body's immune system fight the virus and reduce a key viral marker. The trial was terminated early and did not proceed to later phases.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Antwerp, 2650, Belgium
GSK Investigational Site

Brussels, 1000, Belgium
GSK Investigational Site

Brussels, 1070, Belgium
GSK Investigational Site

Edegem, 2650, Belgium
GSK Investigational Site

Ghent, 9000, Belgium
GSK Investigational Site

Leuven, 3000, Belgium
GSK Investigational Site

Clichy, 92118, France
GSK Investigational Site

Créteil, 94010, France
GSK Investigational Site

Lyon, 69317, France
GSK Investigational Site

Strasbourg, 67091, France
GSK Investigational Site

Berlin, 10787, Germany
GSK Investigational Site

Bonn, 53127, Germany
GSK Investigational Site

Essen, 45122, Germany
GSK Investigational Site

Frankfurt, 60590, Germany
GSK Investigational Site

Hamburg, 20246, Germany
GSK Investigational Site

Mainz, 55131, Germany
GSK Investigational Site

Pokfulam, Hong Kong
GSK Investigational Site

Krakow, 31-202, Poland
GSK Investigational Site

Mysłowice, 41-400, Poland
GSK Investigational Site

Poznan, 60-185, Poland
GSK Investigational Site

Łańcut, 37-100, Poland
GSK Investigational Site

Barcelona, 08011, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Granada, 18016, Spain
GSK Investigational Site

Madrid, 28006, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28222, Spain
GSK Investigational Site

Palma de Mallorca, 07120, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

TorrejOn Ardoz Madrid, 28850, Spain
GSK Investigational Site

Taichung, 40447, Taiwan
GSK Investigational Site

Taichung, 40705, Taiwan
GSK Investigational Site

Tainan, 704, Taiwan
GSK Investigational Site

Taipei, 112, Taiwan
GSK Investigational Site

Taoyuan District, 333, Taiwan
GSK Investigational Site

Bangkok, 10330, Thailand
GSK Investigational Site

Chiang Mai, 50200, Thailand
GSK Investigational Site

London, E1 1BB, United Kingdom
GSK Investigational Site

London, SW17 0QT, United Kingdom
GSK Investigational Site

Nottingham, NG7 2UH, United Kingdom

Conditions

Explore the condition pages connected to this study.

HEPATITIS B, CHRONIC